Abstract
Various supramolecular systems can be used as drug carriers to alter physicochemical and pharmacokinetic characteristics of drugs. Representative supramolecular systems that can be used for this purpose include surfactant/polymer micelles, (micro)emulsions, liposomes, layer-by-layer assemblies, and various molecular conjugates. Notably, liposomes are established supramolecular drug carriers, which have already been marketed in formulations including AmBisome® (for treatment of fungal infection), Doxil® (for Kaposi’s sarcoma), and Visudyne® (for age-related macular degeneration and choroidal neovascularization). Microemulsions have been used oral drug delivery of poorly soluble drugs due to improvements in bioavailability and predictable of absorption behavior. Neoral®, an immunosuppressant used after transplant operations, is one of the most famous microemulsion-based drugs. Polymer micelles are being increasingly investigated as novel drug carriers and some formulations have already been tested in clinical trials. Supramolecular systems can be functionalized by designing the constituent molecules to achieve efficient delivery of drugs to desired sites in the body. In this review, representative supramolecular drug delivery systems, that may improve usability of candidate drugs or add value to existing drugs, are introduced.
Keywords: Drug delivery, emulsion, microemulsion, hybrid, micelle, polymer micelle, layer-by-layer, liposome, molecular conjugate, cyclodextrin, self-assembly, supramolecular chemistry
Current Medicinal Chemistry
Title:Supramolecular Approaches for Drug Development
Volume: 19 Issue: 15
Author(s): K. Kawakami, M. Ebara, H. Izawa, N. M. Sanchez-Ballester, J. P. Hill, K. Ariga
Affiliation:
Keywords: Drug delivery, emulsion, microemulsion, hybrid, micelle, polymer micelle, layer-by-layer, liposome, molecular conjugate, cyclodextrin, self-assembly, supramolecular chemistry
Abstract: Various supramolecular systems can be used as drug carriers to alter physicochemical and pharmacokinetic characteristics of drugs. Representative supramolecular systems that can be used for this purpose include surfactant/polymer micelles, (micro)emulsions, liposomes, layer-by-layer assemblies, and various molecular conjugates. Notably, liposomes are established supramolecular drug carriers, which have already been marketed in formulations including AmBisome® (for treatment of fungal infection), Doxil® (for Kaposi’s sarcoma), and Visudyne® (for age-related macular degeneration and choroidal neovascularization). Microemulsions have been used oral drug delivery of poorly soluble drugs due to improvements in bioavailability and predictable of absorption behavior. Neoral®, an immunosuppressant used after transplant operations, is one of the most famous microemulsion-based drugs. Polymer micelles are being increasingly investigated as novel drug carriers and some formulations have already been tested in clinical trials. Supramolecular systems can be functionalized by designing the constituent molecules to achieve efficient delivery of drugs to desired sites in the body. In this review, representative supramolecular drug delivery systems, that may improve usability of candidate drugs or add value to existing drugs, are introduced.
Export Options
About this article
Cite this article as:
K. Kawakami, M. Ebara, H. Izawa, N. M. Sanchez-Ballester, J. P. Hill, K. Ariga , Supramolecular Approaches for Drug Development, Current Medicinal Chemistry 2012; 19 (15) . https://dx.doi.org/10.2174/092986712800269254
DOI https://dx.doi.org/10.2174/092986712800269254 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs
Anti-Cancer Agents in Medicinal Chemistry When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics Laparoscopic Approach for Surgical Staging in Early Endometrial Cancer
Current Women`s Health Reviews Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Flavonoids Active Against Osteosarcoma: A Review of the Molecular Mechanisms Involved
Current Pharmaceutical Design Immunity to Tumour Antigens
Current Pharmaceutical Design Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Targeting Heme for the Identification of Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Current Management of Fetal and Neonatal Renal Tumors
Current Pediatric Reviews Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design Low-Dose Methotrexate (LD-MTX) in Rheumatology Practice - A Most Widely Misunderstood Drug
Current Rheumatology Reviews HIV-1 IN Inhibitors: 2010 Update and Perspectives
Current Topics in Medicinal Chemistry